Loading…
Plasminogen activator inhibitor type–1 deficiency does not influence the outcome of murine pneumococcal pneumonia
Urokinase-type plasminogen activator (uPA) and its receptor uPAR are components of the fibrinolytic system and are important for an adequate immune response to respiratory tract infection, in part through their role in the migration of inflammatory cells. PA inhibitor–1 (PAI-1) is the predominant in...
Saved in:
Published in: | Blood 2003-08, Vol.102 (3), p.934-939 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c426t-894b0c0e26ebdb7af621909e90067701b6a1dd25d32e9825ddfef4c66bc0bead3 |
---|---|
cites | cdi_FETCH-LOGICAL-c426t-894b0c0e26ebdb7af621909e90067701b6a1dd25d32e9825ddfef4c66bc0bead3 |
container_end_page | 939 |
container_issue | 3 |
container_start_page | 934 |
container_title | Blood |
container_volume | 102 |
creator | Rijneveld, Anita W. Florquin, Sandrine Bresser, Paul Levi, Marcel de Waard, Vivian Lijnen, Roger Van der Zee, Jaring S. Speelman, Peter Carmeliet, Peter van der Poll, Tom |
description | Urokinase-type plasminogen activator (uPA) and its receptor uPAR are components of the fibrinolytic system and are important for an adequate immune response to respiratory tract infection, in part through their role in the migration of inflammatory cells. PA inhibitor–1 (PAI-1) is the predominant inhibitor of soluble and receptor-bound uPA. To determine the role of PAI-1 in host defense against pneumococcal pneumonia, the following studies were performed: (1) Patients with unilateral community-acquired pneumonia demonstrated elevated PAI-1 concentrations together with decreased PA activity in bronchoalveolar lavage fluid (BALF) obtained from the infected, but not from the contralateral, site. (2) Mice with Streptococcus pneumoniae pneumonia displayed elevated PAI-1 protein and mRNA levels in their lungs. (3) PAI-1 gene–deficient mice, however, had an unaltered immune response to pneumococcal pneumonia, as measured by cell recruitment into lungs, bacterial outgrowth, and survival. Furthermore, plasminogen-gene–deficient mice also had an unremarkable defense against pneumococcal pneumonia. These data indicate that pneumonia is associated with inhibition of the fibrinolytic system at the site of the infection secondary to increased production of PAI-1; an intact fibrinolytic response is not required for an adequate host response to respiratory tract infection, however, suggesting that the previously described role of uPA and uPAR are restricted to their function in cell migration. |
doi_str_mv | 10.1182/blood-2003-01-0227 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73425356</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120505715</els_id><sourcerecordid>73425356</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-894b0c0e26ebdb7af621909e90067701b6a1dd25d32e9825ddfef4c66bc0bead3</originalsourceid><addsrcrecordid>eNp9kMtu1TAQhi0EoofCC7BA3sAuMHYSJ5HYoIqbVIkuytryZUyNEvtgO5XOjnfgDfsk9emJ1B2rf8b6ZuT5CHnN4D1jI_-g5xhtwwHaBlgDnA9PyI71fGwAODwlOwAQTTcN7Iy8yPk3AOta3j8nZ4wPwHvgO5KvZpUXH-IvDFSZ4m9ViYn6cOO1P1blsMe7v_8Ytei88RjMgdqImYZYKubmtT4hLTdI41pMXGo6uqzJB6T7gOsSTTRGzVsTvHpJnjk1Z3y15Tn5-eXz9cW35vLH1-8Xny4b03FRmnHqNBhALlBbPSgnOJtgwqleNQzAtFDMWt7bluM01rQOXWeE0AY0Ktuek3envfsU_6yYi1x8NjjPKmBcsxzajvdtLyrIT6BJMeeETu6TX1Q6SAbyqFo-qJZH1RKYPKquQ2-27ate0D6ObG4r8HYDVK73u6SC8fmR6wEGMfaV-3jisLq49ZhkfvCM1ic0Rdro__ePe4E4oAk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73425356</pqid></control><display><type>article</type><title>Plasminogen activator inhibitor type–1 deficiency does not influence the outcome of murine pneumococcal pneumonia</title><source>ScienceDirect (Online service)</source><creator>Rijneveld, Anita W. ; Florquin, Sandrine ; Bresser, Paul ; Levi, Marcel ; de Waard, Vivian ; Lijnen, Roger ; Van der Zee, Jaring S. ; Speelman, Peter ; Carmeliet, Peter ; van der Poll, Tom</creator><creatorcontrib>Rijneveld, Anita W. ; Florquin, Sandrine ; Bresser, Paul ; Levi, Marcel ; de Waard, Vivian ; Lijnen, Roger ; Van der Zee, Jaring S. ; Speelman, Peter ; Carmeliet, Peter ; van der Poll, Tom</creatorcontrib><description>Urokinase-type plasminogen activator (uPA) and its receptor uPAR are components of the fibrinolytic system and are important for an adequate immune response to respiratory tract infection, in part through their role in the migration of inflammatory cells. PA inhibitor–1 (PAI-1) is the predominant inhibitor of soluble and receptor-bound uPA. To determine the role of PAI-1 in host defense against pneumococcal pneumonia, the following studies were performed: (1) Patients with unilateral community-acquired pneumonia demonstrated elevated PAI-1 concentrations together with decreased PA activity in bronchoalveolar lavage fluid (BALF) obtained from the infected, but not from the contralateral, site. (2) Mice with Streptococcus pneumoniae pneumonia displayed elevated PAI-1 protein and mRNA levels in their lungs. (3) PAI-1 gene–deficient mice, however, had an unaltered immune response to pneumococcal pneumonia, as measured by cell recruitment into lungs, bacterial outgrowth, and survival. Furthermore, plasminogen-gene–deficient mice also had an unremarkable defense against pneumococcal pneumonia. These data indicate that pneumonia is associated with inhibition of the fibrinolytic system at the site of the infection secondary to increased production of PAI-1; an intact fibrinolytic response is not required for an adequate host response to respiratory tract infection, however, suggesting that the previously described role of uPA and uPAR are restricted to their function in cell migration.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2003-01-0227</identifier><identifier>PMID: 12702502</identifier><language>eng</language><publisher>Washington, DC: Elsevier Inc</publisher><subject>Adult ; Animals ; Biological and medical sciences ; Bronchoalveolar Lavage Fluid - chemistry ; Bronchoalveolar Lavage Fluid - microbiology ; Case-Control Studies ; Chemotaxis, Leukocyte ; Community-Acquired Infections - immunology ; Female ; Fibrinolysis ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunity ; Immunobiology ; Leukocytes - cytology ; Lung - metabolism ; Lung - pathology ; Male ; Mice ; Mice, Knockout ; Middle Aged ; Modulation of the immune response (stimulation, suppression) ; Plasminogen Activator Inhibitor 1 - deficiency ; Plasminogen Activator Inhibitor 1 - genetics ; Plasminogen Activator Inhibitor 1 - physiology ; Pneumonia, Pneumococcal - immunology ; RNA, Messenger - analysis ; Treatment Outcome</subject><ispartof>Blood, 2003-08, Vol.102 (3), p.934-939</ispartof><rights>2003 American Society of Hematology</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-894b0c0e26ebdb7af621909e90067701b6a1dd25d32e9825ddfef4c66bc0bead3</citedby><cites>FETCH-LOGICAL-c426t-894b0c0e26ebdb7af621909e90067701b6a1dd25d32e9825ddfef4c66bc0bead3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497120505715$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15007685$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12702502$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rijneveld, Anita W.</creatorcontrib><creatorcontrib>Florquin, Sandrine</creatorcontrib><creatorcontrib>Bresser, Paul</creatorcontrib><creatorcontrib>Levi, Marcel</creatorcontrib><creatorcontrib>de Waard, Vivian</creatorcontrib><creatorcontrib>Lijnen, Roger</creatorcontrib><creatorcontrib>Van der Zee, Jaring S.</creatorcontrib><creatorcontrib>Speelman, Peter</creatorcontrib><creatorcontrib>Carmeliet, Peter</creatorcontrib><creatorcontrib>van der Poll, Tom</creatorcontrib><title>Plasminogen activator inhibitor type–1 deficiency does not influence the outcome of murine pneumococcal pneumonia</title><title>Blood</title><addtitle>Blood</addtitle><description>Urokinase-type plasminogen activator (uPA) and its receptor uPAR are components of the fibrinolytic system and are important for an adequate immune response to respiratory tract infection, in part through their role in the migration of inflammatory cells. PA inhibitor–1 (PAI-1) is the predominant inhibitor of soluble and receptor-bound uPA. To determine the role of PAI-1 in host defense against pneumococcal pneumonia, the following studies were performed: (1) Patients with unilateral community-acquired pneumonia demonstrated elevated PAI-1 concentrations together with decreased PA activity in bronchoalveolar lavage fluid (BALF) obtained from the infected, but not from the contralateral, site. (2) Mice with Streptococcus pneumoniae pneumonia displayed elevated PAI-1 protein and mRNA levels in their lungs. (3) PAI-1 gene–deficient mice, however, had an unaltered immune response to pneumococcal pneumonia, as measured by cell recruitment into lungs, bacterial outgrowth, and survival. Furthermore, plasminogen-gene–deficient mice also had an unremarkable defense against pneumococcal pneumonia. These data indicate that pneumonia is associated with inhibition of the fibrinolytic system at the site of the infection secondary to increased production of PAI-1; an intact fibrinolytic response is not required for an adequate host response to respiratory tract infection, however, suggesting that the previously described role of uPA and uPAR are restricted to their function in cell migration.</description><subject>Adult</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Bronchoalveolar Lavage Fluid - chemistry</subject><subject>Bronchoalveolar Lavage Fluid - microbiology</subject><subject>Case-Control Studies</subject><subject>Chemotaxis, Leukocyte</subject><subject>Community-Acquired Infections - immunology</subject><subject>Female</subject><subject>Fibrinolysis</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunity</subject><subject>Immunobiology</subject><subject>Leukocytes - cytology</subject><subject>Lung - metabolism</subject><subject>Lung - pathology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Middle Aged</subject><subject>Modulation of the immune response (stimulation, suppression)</subject><subject>Plasminogen Activator Inhibitor 1 - deficiency</subject><subject>Plasminogen Activator Inhibitor 1 - genetics</subject><subject>Plasminogen Activator Inhibitor 1 - physiology</subject><subject>Pneumonia, Pneumococcal - immunology</subject><subject>RNA, Messenger - analysis</subject><subject>Treatment Outcome</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNp9kMtu1TAQhi0EoofCC7BA3sAuMHYSJ5HYoIqbVIkuytryZUyNEvtgO5XOjnfgDfsk9emJ1B2rf8b6ZuT5CHnN4D1jI_-g5xhtwwHaBlgDnA9PyI71fGwAODwlOwAQTTcN7Iy8yPk3AOta3j8nZ4wPwHvgO5KvZpUXH-IvDFSZ4m9ViYn6cOO1P1blsMe7v_8Ytei88RjMgdqImYZYKubmtT4hLTdI41pMXGo6uqzJB6T7gOsSTTRGzVsTvHpJnjk1Z3y15Tn5-eXz9cW35vLH1-8Xny4b03FRmnHqNBhALlBbPSgnOJtgwqleNQzAtFDMWt7bluM01rQOXWeE0AY0Ktuek3envfsU_6yYi1x8NjjPKmBcsxzajvdtLyrIT6BJMeeETu6TX1Q6SAbyqFo-qJZH1RKYPKquQ2-27ate0D6ObG4r8HYDVK73u6SC8fmR6wEGMfaV-3jisLq49ZhkfvCM1ic0Rdro__ePe4E4oAk</recordid><startdate>20030801</startdate><enddate>20030801</enddate><creator>Rijneveld, Anita W.</creator><creator>Florquin, Sandrine</creator><creator>Bresser, Paul</creator><creator>Levi, Marcel</creator><creator>de Waard, Vivian</creator><creator>Lijnen, Roger</creator><creator>Van der Zee, Jaring S.</creator><creator>Speelman, Peter</creator><creator>Carmeliet, Peter</creator><creator>van der Poll, Tom</creator><general>Elsevier Inc</general><general>The Americain Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030801</creationdate><title>Plasminogen activator inhibitor type–1 deficiency does not influence the outcome of murine pneumococcal pneumonia</title><author>Rijneveld, Anita W. ; Florquin, Sandrine ; Bresser, Paul ; Levi, Marcel ; de Waard, Vivian ; Lijnen, Roger ; Van der Zee, Jaring S. ; Speelman, Peter ; Carmeliet, Peter ; van der Poll, Tom</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-894b0c0e26ebdb7af621909e90067701b6a1dd25d32e9825ddfef4c66bc0bead3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Bronchoalveolar Lavage Fluid - chemistry</topic><topic>Bronchoalveolar Lavage Fluid - microbiology</topic><topic>Case-Control Studies</topic><topic>Chemotaxis, Leukocyte</topic><topic>Community-Acquired Infections - immunology</topic><topic>Female</topic><topic>Fibrinolysis</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunity</topic><topic>Immunobiology</topic><topic>Leukocytes - cytology</topic><topic>Lung - metabolism</topic><topic>Lung - pathology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Middle Aged</topic><topic>Modulation of the immune response (stimulation, suppression)</topic><topic>Plasminogen Activator Inhibitor 1 - deficiency</topic><topic>Plasminogen Activator Inhibitor 1 - genetics</topic><topic>Plasminogen Activator Inhibitor 1 - physiology</topic><topic>Pneumonia, Pneumococcal - immunology</topic><topic>RNA, Messenger - analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rijneveld, Anita W.</creatorcontrib><creatorcontrib>Florquin, Sandrine</creatorcontrib><creatorcontrib>Bresser, Paul</creatorcontrib><creatorcontrib>Levi, Marcel</creatorcontrib><creatorcontrib>de Waard, Vivian</creatorcontrib><creatorcontrib>Lijnen, Roger</creatorcontrib><creatorcontrib>Van der Zee, Jaring S.</creatorcontrib><creatorcontrib>Speelman, Peter</creatorcontrib><creatorcontrib>Carmeliet, Peter</creatorcontrib><creatorcontrib>van der Poll, Tom</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rijneveld, Anita W.</au><au>Florquin, Sandrine</au><au>Bresser, Paul</au><au>Levi, Marcel</au><au>de Waard, Vivian</au><au>Lijnen, Roger</au><au>Van der Zee, Jaring S.</au><au>Speelman, Peter</au><au>Carmeliet, Peter</au><au>van der Poll, Tom</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasminogen activator inhibitor type–1 deficiency does not influence the outcome of murine pneumococcal pneumonia</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2003-08-01</date><risdate>2003</risdate><volume>102</volume><issue>3</issue><spage>934</spage><epage>939</epage><pages>934-939</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Urokinase-type plasminogen activator (uPA) and its receptor uPAR are components of the fibrinolytic system and are important for an adequate immune response to respiratory tract infection, in part through their role in the migration of inflammatory cells. PA inhibitor–1 (PAI-1) is the predominant inhibitor of soluble and receptor-bound uPA. To determine the role of PAI-1 in host defense against pneumococcal pneumonia, the following studies were performed: (1) Patients with unilateral community-acquired pneumonia demonstrated elevated PAI-1 concentrations together with decreased PA activity in bronchoalveolar lavage fluid (BALF) obtained from the infected, but not from the contralateral, site. (2) Mice with Streptococcus pneumoniae pneumonia displayed elevated PAI-1 protein and mRNA levels in their lungs. (3) PAI-1 gene–deficient mice, however, had an unaltered immune response to pneumococcal pneumonia, as measured by cell recruitment into lungs, bacterial outgrowth, and survival. Furthermore, plasminogen-gene–deficient mice also had an unremarkable defense against pneumococcal pneumonia. These data indicate that pneumonia is associated with inhibition of the fibrinolytic system at the site of the infection secondary to increased production of PAI-1; an intact fibrinolytic response is not required for an adequate host response to respiratory tract infection, however, suggesting that the previously described role of uPA and uPAR are restricted to their function in cell migration.</abstract><cop>Washington, DC</cop><pub>Elsevier Inc</pub><pmid>12702502</pmid><doi>10.1182/blood-2003-01-0227</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-4971 |
ispartof | Blood, 2003-08, Vol.102 (3), p.934-939 |
issn | 0006-4971 1528-0020 |
language | eng |
recordid | cdi_proquest_miscellaneous_73425356 |
source | ScienceDirect (Online service) |
subjects | Adult Animals Biological and medical sciences Bronchoalveolar Lavage Fluid - chemistry Bronchoalveolar Lavage Fluid - microbiology Case-Control Studies Chemotaxis, Leukocyte Community-Acquired Infections - immunology Female Fibrinolysis Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunity Immunobiology Leukocytes - cytology Lung - metabolism Lung - pathology Male Mice Mice, Knockout Middle Aged Modulation of the immune response (stimulation, suppression) Plasminogen Activator Inhibitor 1 - deficiency Plasminogen Activator Inhibitor 1 - genetics Plasminogen Activator Inhibitor 1 - physiology Pneumonia, Pneumococcal - immunology RNA, Messenger - analysis Treatment Outcome |
title | Plasminogen activator inhibitor type–1 deficiency does not influence the outcome of murine pneumococcal pneumonia |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A57%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasminogen%20activator%20inhibitor%20type%E2%80%931%20deficiency%20does%20not%20influence%20the%20outcome%20of%20murine%20pneumococcal%20pneumonia&rft.jtitle=Blood&rft.au=Rijneveld,%20Anita%20W.&rft.date=2003-08-01&rft.volume=102&rft.issue=3&rft.spage=934&rft.epage=939&rft.pages=934-939&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2003-01-0227&rft_dat=%3Cproquest_cross%3E73425356%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c426t-894b0c0e26ebdb7af621909e90067701b6a1dd25d32e9825ddfef4c66bc0bead3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73425356&rft_id=info:pmid/12702502&rfr_iscdi=true |